The press release machine loves a clean, triumphant narrative. England is supposedly on the brink of eliminating hepatitis C, marching hand-in-hand toward a shiny, virus-free horizon ahead of the global pack. NHS leaders pop metaphorical champagne, policy wonks draft self-congratulatory briefs, and the public nods along, relieved that another ancient plague has been managed out of existence by sheer bureaucratic willpower and bulk-purchased direct-acting antivirals.
It is a comforting bedtime story. It is also entirely detached from the reality on the ground.
I have spent years watching public health initiatives crash against the jagged realities of human behavior, and I can tell you that the official narrative of impending elimination is a masterclass in institutional delusion. We are not beating hepatitis C. We are simply getting very good at curing the easy-to-reach populations while actively ignoring the structural machinery that generates new infections every single day.
If you want to know why England will miss its elimination targets—or worse, declare victory while transmission quietly thrives in the shadows—you have to stop listening to the health bureaucrats and start looking at the mechanics of failure.
The Mirage of the Cascade of Care
Let us look at the core argument of the mainstream consensus. The logic goes like this: England centralized its procurement of direct-acting antivirals, struck commercial deals with pharmaceutical companies, decentralized testing into community clinics, and drove down prevalence rates across the board. Therefore, the math points inexorably to zero.
Mathematically, it sounds airtight. Practically, it ignores how populations actually function.
The entire architecture of the NHS hepatitis C elimination plan relies on a linear cascade of care: diagnose, link to care, prescribe, cure. But human lives, especially the lives of people caught in active marginalization, are non-linear. They are chaotic, fractured, and fiercely resistant to standardized clinical pathways.
When a clinic boasts about treating a thousand patients, it seldom highlights the three thousand others who walked out of the door after the initial antibody test, never to return for the confirmatory RNA draw. It glosses over the transient populations who change postcodes, lose phones, and cycle through the penal system faster than an outreach worker can track them.
We have built a system designed for compliant patients in a non-compliant world.
The Institutional Blind Spot
To understand why the elimination target is a ghost story, you have to look at where the new infections are actually happening. The medical establishment loves to talk about historical cohorts—the generation of people who acquired the virus through past injecting drug use or contaminated blood products decades ago. Curing them is an administrative triumph, but it is an epidemiological rearview mirror.
The bleeding edge of transmission today is not sitting neatly in a suburban GP surgery. It is concentrated in active, chaotic street-level drug markets, homeless hostels, and prisons—environments where structural violence makes health a secondary concern to basic survival.
Let us be precise about the failure points.
First, the prison estate remains a revolving door of infection and reinfection. While testing and treatment programs inside British prisons have improved dramatically, the moment a person is released—often with zero discharge planning, no housing, and immediate destitution—their vulnerability skyrockets. They return to environments where sharing injecting equipment is a daily logistical reality. Curing someone inside a prison cell and releasing them back onto the street without structural support is like bailing out a sinking boat with a perforated teaspoon.
Second, the criminalization of drug use casts a long, toxic shadow over prevention. When possession of paraphernalia or substances carries the threat of police harassment, individuals hide their practices. They avoid harm reduction sites. They rush injections, leading to a higher rate of damaged veins and shared equipment. As long as the state treats a public health crisis as a criminal justice issue, hepatitis C will outpace our prescription pads.
The Dangerous Allure of Sunk Cost Fallacy
Public health campaigns suffer from a severe psychological affliction: the sunk cost fallacy on a national scale. Once a government commits billions to a specific intervention—in this case, bulk drug procurement and centralized micro-elimination projects—the entire institutional apparatus becomes incapable of admitting its limitations.
To suggest that elimination is failing requires admitting that the foundational strategy is incomplete. Bureaucracies hate incomplete truths. They prefer comforting metrics. If you test enough people in low-prevalence settings, your overall percentage of cured individuals looks stellar on an annual report, even as high-risk transmission networks burn hot beneath the official radar.
I have watched regional health authorities celebrate a drop in overall prevalence while ignoring localized spikes among younger cohorts of people who inject drugs. They average out the data, smoothing over the jagged peaks of localized crises with the comfortable blanket of national averages.
Averages do not transmit viruses. Individuals do. And transmission is hyper-concentrated in pockets that mainstream public health is structurally unequipped to penetrate.
What Real Intervention Actually Looks Like
If we stopped lying to ourselves about imminent victory, what would we actually do? It requires dismantling the current playbook and replacing it with something radically decentralized and radically empathetic.
Decentralization cannot just mean putting a FibroScan machine in a mobile van that visits a city center once a month. It means embedding care directly into the hands of peers—people with lived experience who hold genuine trust within marginalized communities. Trust is the only currency that matters in this space, and the NHS does not manufacture it.
Furthermore, we need to decouple healthcare delivery from any requirement of abstinence or behavioral modification. The medical paternalism that demands a patient clean up their act before they deserve a twelve-week course of curative pills is still alive and well, disguised as clinical protocol.
Imagine a scenario where every needle exchange, every homeless shelter, and every police custody suite dispensed direct-acting antivirals on demand, with no blood tests required for initiation, no ID checks, and no bureaucratic gatekeeping. We treat acute infections with antibiotics on clinical suspicion; we should treat hepatitis C with the exact same ruthless speed. If a patient is at risk, hand them the cure before they walk out the door. No waiting for lab results that take three weeks to process. No second appointments.
The Cost of Premature Celebration
The danger of declaring victory too early is not just reputational. It is financial and operational abandonment.
Once a disease is labeled as "eliminated" or "under control," funding evaporates. Prevention budgets are slashed, outreach teams are disbanded, and specialized staff are reassigned to the next health panic of the decade. When the inevitable resurgence hits—fueled by untreated transmission chains in hidden populations—the infrastructure to fight it will be gone, dismantled by politicians eager to cash in on a premature success story.
England is not eliminating hepatitis C. England is treating the low-hanging fruit, patting itself on the back, and ignoring the roots of the tree.
Until we fix the prisons, until we decriminalize survival, and until we stop designing healthcare systems for the people who need them least, the narrative of elimination remains what it has always been: a comforting illusion for people who never have to live with the virus.
Stop measuring success by the pills you hand out. Measure it by the fires you actually put out.
